Global Initiative Orders 120 Million Abbott, SD Biosensor COVID-19 Rapid Antigen Tests
Tests will be priced at under $5 each for low- and middle-income countries.
You may also be interested in...
Abbott plans to deliver 30 million BinaxNOW prescription, at-home rapid tests in the first quarter of 2021; 90 million more in the second quarter.
Cue’s point-of-care molecular test earned an FDA emergency use authorization in June.
A resolution at the latest World Health Assembly meeting on providing universal and equitable access to COVID-19 technologies, medicines and vaccines has been adopted, along with an agreement to review the World Health Organization’s response to the crisis.